Epidermal penetration and protoporphyrin IX formation of two different 5-aminolevulinic acid formulations in ex vivo human skin

Photodiagnosis and Photodynamic Therapy

Volumn 14, Issue , 2016, Pages 40-46

  Schmitz, Lutz ^a,b   Novak, Ben ^a   Hoeh, Ann Kathrin ^a   Luebbert, Herman ^a   Dirschka, Thomas ^b,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CentroDerm GmbH   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

5 Aminolevulinic acid; BF 200 ALA; Nanoemulsion; Organotypic skin culture; Photodynamic Therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; PROTOPORPHYRIN; PHOTOSENSITIZING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREAM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; EX VIVO STUDY; FEMALE; FLUORESCENCE MICROSCOPY; FLUOROMETRY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NANOEMULSION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN PENETRATION; STRATUM CORNEUM; BIOLOGICAL MODEL; CLASSIFICATION; DRUG EFFECTS; EPIDERMIS; PHOTOCHEMOTHERAPY; SKIN;

ADULT; AMINOLEVULINIC ACID; EPIDERMIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SKIN;

EID: 84958981549     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.11.004     Document Type: Article

References (31)

1. Ratushny V., Gober M.D., Hick R., Ridky T.W., Seykora J.T. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J. Clin. Invest. 2012, 122:464-472.
2. Kasper M., Jaks V., Hohl D., Toftgard R. Basal cell carcinoma-molecular biology and potential new therapies. J. Clin. Invest. 2012, 122:455-463.
3. Uehlinger P., Zellweger M., Wagnieres G., Juillerat-Jeanneret L., van den B.H., Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B 2000, 54:72-80.
4. Kaliszewski M., Kwasny M., Juzeniene A., Juzenas P., Graczyk A., Ma L.W., et al. Biological activity of 5-aminolevulinic acid and its methyl ester after storage under different conditions. J. Photochem. Photobiol. B 2007, 87:67-72.
5. Schulten R., Novak B., Schmitz B., Lubbert H. Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385(10):969-979.
6. Fritsch C., Homey B., Stahl W., Lehmann P., Ruzicka T., Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem. Photobiol. 1998, 68:218-221.
7. Novak B., Schulten R., Lubbert H. Delta-Aminolevulinic acid and its methyl ester induce the formation of protoporphyrin IX in cultured sensory neurones. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 384:583-602.
8. Wu Y., Li Y.H., Gao X.H., Chen H.D. The application of nanoemulsion in dermatology: an overview. J. Drug Target. 2013, 21:321-327.
9. Maisch T., Worlicek C., Babilas P., Landthaler M., Szeimies R.M. A HCl/alcohol formulation increased 5-aminolevulinic acid skin distribution using an ex vivo full thickness porcine skin model. Exp. Dermatol. 2008.
10. Maisch T., Santarelli F., Schreml S., Babilas P., Szeimies R.M. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp. Dermatol. 2010, 19:e302-e305.
11. Meyer W. Comments on the suitability of swine skin as a biological model for human skin. Hautarzt 1996, 47:178-182.
12. Eggleston T.A., Roach W.P., Mitchell M.A., Smith K., Oler D., Johnson T.E. Comparison of two porcine (Sus scrofa domestica) skin models for in vivo near-infrared laser exposure. Comp. Med. 2000, 50:391-397.
13. Bronaugh R.L., Stewart R.F., Congdon E.R. Methods for in vitro percutaneous absorption studies: II animal models for human skin. Toxicol. Appl. Pharm. 1982, 62:481-488.
14. Babilas P., Landthaler M., Szeimies R.M. Photodynamic therapy in dermatology. Eur. J. Dermatol. 2006, 16:340-348.
15. Middelburg T.A., Van Zaane F., De Bruijn H.S., Van Der Ploeg-van den Heuvel A., Sterenborg H.J., Neumann H.A., et al. Fractionated illumination at low fluence rate photodynamic therapy in mice. Photochem. Photobiol. 2010, 86:1140-1146.
16. Togsverd-Bo K., Idorn L.W., Philipsen P.A., Wulf H.C., Haedersdal M. Protoporphyrin IX formation and photobleaching in different layers of normal human skin: methyl- and hexylaminolevulinate and different light sources. Exp. Dermatol. 2012, 21:745-750.
17. Campbell S.M., Pye A., Horton S., Matthew J., Helliwell P., Curnow A. A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J. Environ. Pathol. Toxicol. Oncol. 2007, 26:295-303.
18. Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br. J. Dermatol. 2012, 166:137-146.
19. Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br. J. Dermatol. 2013, 168:825-836.
20. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003, 63:1727-1730.
21. Cockerell C.J., Wharton J.R. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J. Drugs Dermatol. 2005, 4:462-467.
22. Ehrig T., Cockerell C., Piacquadio D., Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol. Surg. 2006, 32:1261-1265.
23. Feldman S.R., Fleischer A.B. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011, 87:201-207.
24. Cai H., Wang Y.X., Sun P., Yang Z.Y., Tian R., Liu X.Y., et al. Photodynamic therapy for facial actinic keratosis: a clinical and histological study in Chinese patients. Photodiagn. Photodyn. Ther. 2013, 10:260-265.
25. Gupta A.K., Paquet M., Villanueva E., Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst. Rev. 2012, 12. CD004415.
26. Kaliszewski M., Kwasny M., Kaminski J., Dabrowski Z., Burdziakowska E. The stability of 5-aminolevulinic acid and its ester derivatives. Acta Pol. Pharm. 2004, 61:15-19.
27. Lebonvallet N., Jeanmaire C., Danoux L., Sibille P., Pauly G., Misery L. The evolution and use of skin explants: potential and limitations for dermatological research. Eur. J. Dermatol. 2010, 20:671-684.
28. Whitton J.T., Everall J.D. The thickness of the epidermis. Br. J. Dermatol. 1973, 89:467-476.
29. Nissen C.V., Philipsen P.A., Wulf H.C., Protoporphyrin I.X. Formation after topical application of methyl aminolaevulinate and BF-200 aminolaevulinic acid declines with age. Br. J. Dermatol. 2015.
30. Waters J.C. Accuracy and precision in quantitative fluorescence microscopy. J. Cell Biol. 2009, 185:1135-1148.
31. Forster B., Klein A., Szeimies R.M., Maisch T. Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium: YAG laser ablation of the stratum corneum: continuous versus fractional ablation. Exp. Dermatol. 2010, 19:806-812.